Comparative Pharmacology
Head-to-head clinical analysis: FLEXERIL versus NORFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLEXERIL versus NORFLEX.
FLEXERIL vs NORFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Orphenadrine is a centrally acting skeletal muscle relaxant with anticholinergic and local anesthetic properties. It acts primarily by blocking cholinergic receptors in the central nervous system, particularly in the reticular activating system, leading to reduced muscle spasm and rigidity.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Adults: 100 mg orally twice daily. Maximum dose: 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal elimination half-life: 15-20 hours. Clinical context: Allows twice-daily dosing; steady-state reached in 3-5 days.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; <10% unchanged in feces.
Category C
Category C
Muscle Relaxant
Muscle Relaxant